Literature DB >> 22014206

Strategic pain management: the identification and development of the IAHPC opioid essential prescription package.

Ernesto Vignaroli1, Michael I Bennett, Cheryl Nekolaichuk, Liliana De Lima, Roberto Wenk, Carla I Ripamonti, Eduardo Bruera.   

Abstract

The aim of this study was to determine by consensus the components of an opioid essential prescription package (OEPP) to be used when initiating a prescription for the control of moderate to severe chronic pain. Palliative care physicians (n=60) were sampled from the International Association for Hospice and Palliative Care (IAHPC) membership list to represent a range of countries of varying economic levels and diverse geographical regions. Using a Delphi study method, physicians were asked to rank preferences of drug and dosing schedule for first-line opioid, antiemetic, and laxative for the treatment of adults with chronic pain due to cancer and other life-threatening conditions. Overall response rates after two Delphi survey rounds were 95% (n=57) and 82% (n=49), respectively. A consensus (set at ≥75% agreement) was reached to include morphine as first-line opioid at a dose of 5 mg orally every 4 hours. Consensus was reached to include metoclopramide as a first-line antiemetic, but there was no consensus on "regular" or "as needed" administration. No consensus was reached regarding a first-line laxative, but a combination of senna and docusate secured 59% agreement. There was consensus (93% agreement) that laxatives should always be given regularly when opioid treatment is started. Further work is needed to establish a recommended dose of metoclopramide and a type and dose of laxative. The resulting OEPP is international in scope and is designed to ensure that opioids are better tolerated by reducing adverse effects of opioids, which could lead to more sustained improvements in pain management.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22014206     DOI: 10.1089/jpm.2011.0296

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  3 in total

1.  A randomized, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients.

Authors:  Satoshi Inoue; Yoji Saito; Satoru Tsuneto; Etsuko Aruga; Hiroshi Takahashi; Mitsutoshi Uemori
Journal:  Jpn J Clin Oncol       Date:  2018-06-01       Impact factor: 3.019

2.  Attributes of analgesics for emergency pain relief: results of the Consensus on Management of Pain Caused by Trauma Delphi initiative.

Authors:  Keith Porter; Bart Morlion; Mark Rolfe; Christoph Dodt
Journal:  Eur J Emerg Med       Date:  2020-02       Impact factor: 4.106

3.  A randomized, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain reLief).

Authors:  Satoshi Inoue; Yoji Saito; Satoru Tsuneto; Etsuko Aruga; Azusa Ide; Yasuyuki Kakurai
Journal:  J Pain Res       Date:  2017-08-18       Impact factor: 3.133

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.